Qraft Technologies Closes US$146 Million Investment from SoftBank Group Entering into a Strategic Partnership to Accelerate AI in the Asset Management Industry
AI enabled fintech company Qraft Technologies, Inc. (“Qraft” or “the company”) today announced that it has closed a US$146 million investment from SoftBank Group Corp. (“SoftBank”), which includes primary growth capital and secondary capital that will be used to fund share purchases from investors. The proposed transaction is expected to accelerate Qraft’s ongoing expansions into the US and China, while the two parties will also embark upon strategic projects that aim to pursue the possibilities of developing AI-enabled public portfolio management systems for SoftBank.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005190/en/
Marcus Kim, Founder and CEO of Qraft Technologies (Photo: Business Wire)
Headquartered in Seoul, Qraft develops and operates deep learning-based algorithms that provide portfolio weight signals which can be alpha-generative. The company has demonstrated the performance of its proprietary AI engine throughout its NYSE-listed ETFs. Qraft also offers B2B AI solutions ranging from data processing, investment strategy discovery, order execution to investment analysis & reporting that create unique values for global asset managers.
“Qraft can revolutionize the way financial institutions manage public equity assets, by providing their own AI technologies that have been tested and proven in the US equity market,” said Kentaro Matsui, Managing Partner at SB Investment Advisers and former Managing Director at SoftBank Group Corp. “On the back of our extensive AI ecosystem, we are thrilled to partner up with Mr. Kim and the Qraft team and support their mission of disrupting the asset management industry globally.”
Qraft CEO Marcus Kim believes “there will be enormous synergy to be had with SoftBank, the leader in investing in disruptive startups, and public equities management powered by Qraft’s AI. This only marks the start of AI technology fundamentally changing the US $100 trillion asset management industry.”
Robert Nestor, former President of Direxion ETFs and Head of iShares Factor ETF business, who recently took charge of Qraft's US expansion as US CEO, commented, “Qraft’s AI capabilities are second to none in investment management, and it is ripe for disruption with AI’s rapidly evolving capabilities. SoftBank recognizes this with its investment, and together we plan to change asset management.”
To support these effects, Qraft plans to accelerate its global business by hiring top-talents and opening new offices across New York, San Francisco as well as Hong Kong.
About Qraft Technologies
Qraft Technologies, Inc. is on a mission to transform alpha delivery in asset management. From data processing to alpha research and trade signals, Qraft has a track record of developing innovative AI solutions that have been adopted by major financial institutions and turned into successful AI products and services, including one of the leading AI-driven equity ETF platforms and Korea's largest robo-advisor engine provider.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Gregory FCA for Qraft Technologies
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station9.12.2022 20:04:00 CET | Press release
RevBio, Inc., announced that anexperiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS). On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceX’s 26th Commercial Resupply Services (SpaceX CRS-26) mission, sponsored by the ISS National Laboratory. This in vivo research, which will be conducted over the next two months on the ISS, will examine the biomaterial’s ability to regenerate bone when used in a microgravity environment where bone growing conditions and the ability to regenerate new bone tissue is significantly compromised. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005635/en/ RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station. This Experiment will Examine TETRANITE’S Ability to Regenerate Bone under the Condition of
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials9.12.2022 14:00:00 CET | Press release
Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3 In the TNBC cohort of TROPION-PanTumor01 (n=44)
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases9.12.2022 14:00:00 CET | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda’s latest research focuses on improving long-term outcomes for patients with hematologic diseases. Takeda’s presentations will include oral sessions detailing a three-year update of the Phase 3 OPTIC trial demonstrating the efficacy and safety of ICLUSIG® (ponatinib) in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML), and results from a first-in-human Phase 1/2 study evaluating modakafusp alfa (TAK-573) in patients with relapsed / refractory multiple myeloma. “Our latest research is focused on investigating novel mechanisms of action, as well as optimizing approved treatments to improve long-term outcomes and more deeply understand and address unmet needs for patients across a range of hematologic diseases,” said Awny Farajallah, M.D., Head of Global Med
Tecnotree Advances to Acquire Top AIML Platform - CognitiveScale in North America to further Enhance 5G Use case Penetration9.12.2022 13:23:00 CET | Press release
Tecnotree is a market leader in 5G digital Business Support Systems (BSS), with AI/ML capabilities and multi-cloud extensibility. Tecnotree’s global footprint with over 90 Telecom customers in 70 countries around the world, supports ecosystems of over 1 billion subscribers. Tecnotree is the first Digital Platform Service provider to be Platinum Badge Certified by TM Forum for Real-world Open API standards. The company also provides B2B2X partner ecosystem and fintech services for monetization beyond connectivity across gaming, healthcare, education, and banking. Tecnotree has been recognized by Gartner for revenue management and monetization as well as for customer experience management solutions and enjoys the position of a leading stock on the Helsinki Nasdaq since 2020. CognitiveScale (CS) is United States based pioneer in the space of AI Engineering and provides solutions for scalable enterprise AI development and deployment. CognitiveScale is backed by over 100 granted AI patents
Another Sustainability Award for NTHU9.12.2022 10:00:00 CET | Press release
National Tsing Hua University (NTHU) in Taiwan has been awarded the Taiwan University Sustainability Award for the second year in a row! The Award was announced at the 15th Taiwan Corporate Sustainability Awards (TCSA) recently held by the Taiwan Institute for Sustainable Energy (TAISE). Standing out amongst the 47 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions received the University Sustainability Report Gold Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221209005001/en/ NTHU president W. John Kao (right) accepting the Taiwan University Sustainability Award from You Si-kun, president of the Legislative Yuan. (Photo: National Tsing Hua University) The judges cited the exemplary way in which NTHU has adopted an innovative approach to integrating classroom learning, campus activities and social service, thereby enriching students’ education and cre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom